OKYO Pharma's neuropathic corneal pain study greenlit by FDA

OKYO Pharma (NASDAQ: OKYO) secured positive feedback from an FDA Type C meeting and is set to launch a Phase 2b/3 trial for neuropathic corneal pain with guidance to enroll 120 subjects and a clarified primary endpoint. Management expects first patient dosing by mid-2026, potential study completion by year-end, and top-line results in Q1 2027, shifting the company's focus to clinical execution and de-risking the development pathway.

Analysis

Contrarian angles: the market may underappreciate clinical execution risk despite the positive meeting — a cleared Type C does not immunize against subjective endpoint failure or high placebo; historical parallels include pain/neuropathic programs that had positive regulatory dialogues yet failed in pivotal readouts. Conversely, upside is asymmetric: a positive topline could drive acquisition interest (biotech M&A multiples >2x post‑pivotal) and rapid rerating. Unintended consequences: early enthusiasm can mask impending dilution — if cash <12 months runway (check next 10‑Q), downside from a financing at subcurrent levels could exceed clinical risk.

Key Decisions for Investors

• Establish a 2–3% portfolio allocation long in OKYO (NASDAQ:OKYO) ahead of expected first‑patient, first‑visit (FPFV) mid‑2026; set a tactical stop loss at 50% downside from entry and plan to take ~30% profits on FPFV confirmation.
• Implement a hedged options trade: buy a Mar/Apr 2027 call spread on OKYO to capture upside to Q1‑2027 topline while limiting premium; sell a short‑dated (3–6 month) call to finance ~30–50% of the spread cost. Close positions on topline or if enrollment misses by >90 days.
• Run a relative value pair: long OKYO equal‑dollar vs short 0.5x exposure to IBB (or a small‑cap biotech ETF) to neutralize market beta; rebalance if sector volatility (VIX or XVOL) diverges >25% from historical 60‑day level.
• Before adding exposure, confirm two proximate data points in the next 30–90 days: (1) company cash runway disclosure sufficient to fund the trial through topline without >20% dilution probability, and (2) first 3–5 site activations or a public site‑initiation update; if either fails, reduce exposure by 50%.